Anyone who just came across A2 will be impressed with its value at the current share price. On a basic level, a forward PE of 28 assuming 47c per share, revenue growth of between 30-40% in at least FY20/21 and still an impressive EBITDA margin of 28%, which should scale up in Fy21 and given the current NZD position provides real upside.
Non-owners who aren't bearish on A2 must see this as good value when you balance the global opp vs potential risks.
As a holder I'm actually pleased we're getting down to levels that make it attractive to buy more rather than ruing not having bought more if we were making ATHs.
- Forums
- ASX - By Stock
- A2M
- Chart Update
Chart Update, page-7390
-
-
- There are more pages in this discussion • 17,841 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
|
|||||
Last
$6.80 |
Change
-0.055(0.80%) |
Mkt cap ! $4.937B |
Open | High | Low | Value | Volume |
$6.88 | $6.90 | $6.79 | $1.918M | 280.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 5398 | $6.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.80 | 11205 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 11586 | 6.790 |
15 | 24868 | 6.780 |
13 | 22334 | 6.770 |
7 | 21111 | 6.760 |
9 | 17464 | 6.750 |
Price($) | Vol. | No. |
---|---|---|
6.800 | 9684 | 11 |
6.810 | 28024 | 16 |
6.820 | 17208 | 13 |
6.830 | 14600 | 12 |
6.840 | 41059 | 12 |
Last trade - 11.30am 16/07/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online